Improved Control Of Activation And Expansion Of Tregs For Use In Cell Therapy Applications

CTS Dynabeads CD3/CD28 is a platform technology applied for ex vivo manufacture of polyclonal T cells for use in various adoptive cell therapies. Here we present a new bead, CTS Dynabeads Treg Xpander, which is a modification of this platform to specifically activate and expand regulatory T cells (Tregs).

Tregs (CD4+CD25+FOXP3+) are a suppressive subset of CD4+ T helper cells important for the regulation of immune responses. Tregs are proven highly effective in preventing graft versus host disease (GvHD) and autoimmunity in murine models. These findings, together with the recent successes in adoptive T-cell therapy to treat severe blood cancers, have increased the interest of using Tregs for autologous and allogenic therapies.

As the relative frequency of Tregs in peripheral blood is approximately 1-2% of the total lymphocyte population, ex vivo expansion of Tregs prior to adoptive transfer will be necessary for most clinical applications.